ProKidney Corp., a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), has announced it will invest $485 million to build a new biomanufacturing facility in Greensboro, North Carolina, creating 330 new jobs in Guilford County. The manufacturing facility will allow the company to commercialize its cell therapy.
“We are thrilled that a homegrown company like ProKidney will continue its game-changing work in North Carolina,” said Christopher Chung, CEO of the Economic Development Partnership of North Carolina (EDPNC). “North Carolina’s highly trained workforce, top-notch education systems and public and private partnerships offer what companies like ProKidney need to be innovative and successful.”
ProKidney uses a patented and proprietary cell therapy platform called REACT (REnal Autologous Cell Therapy) to help treat CKD by preserving the kidney function of patients with a high risk of kidney failure, by using the patient’s own kidney cells. REACT is currently undergoing phase 3 trials with a planned completion date of February 2027. The company was founded in 2018 and is headquartered in Winston-Salem.
While salaries will vary by position, the average wage will be $74,636, which is higher than Guilford County’s average wage of $57,190. The EDPNC provided support to the project as real estate, business costs and incentives were evaluated as well as coordinated input from partners.
The Economic Development Partnership of North Carolina would like to recognize the North Carolina Department of Commerce as well as other key partners involved in this project, including the North Carolina General Assembly, the North Carolina Community College System, the North Carolina Department of Transportation, Guilford County, the City of Greensboro, Guilford County Economic Development Alliance, the Greensboro Chamber of Commerce, Guilford Technical Community College, Duke Energy and the North Carolina Biotechnology Center.